

DESCRIPTION

Source Chinese Hamster Ovary cell line, CHO-derived
Ser293-His431
Accession # P18075

N-terminal Sequence Analysis Ser293

Structure / Form Disulfide-linked homodimer. Biotinylated protein via amines

Predicted Molecular Mass 16 kDa (unlabeled)

SPECIFICATIONS

SDS-PAGE 15-24 kDa, reducing conditions

Activity Measured by its binding ability in a functional ELISA.
In a Streptavidin coated plate (Catalog # CP004), when Biotinylated Recombinant Human BMP-7 is used at 0.25 µg/mL, it binds Recombinant Human Activin RIA/ALK-2 Fc Chimera (Catalog # 637-AR) with an ED₅₀ of 0.15-0.9 µg/mL.

Measured by its ability to induce alkaline phosphatase production by ATDC5 mouse chondrogenic cells. Nakamura, K. *et al.* (1999) Exp. Cell Res. **250**:351.
The ED₅₀ for this effect is 0.1-0.6 µg/mL.

Endotoxin Level <0.01 EU per 1 µg of the protein by the LAL method.

Purity >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in HCl with BSA as a carrier protein. See Certificate of Analysis for details.

PREPARATION AND STORAGE


Reconstitution Reconstitute at 100 µg/mL in 4 mM HCl.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA



BACKGROUND

Bone morphogenetic protein 7 (BMP-7), also known as osteogenic protein 1 (OP-1), is a widely expressed TGF- β superfamily member with important functions during embryogenesis, in the adult, and in disease (1, 2). Human BMP-7 is synthesized with a 29 amino acid (aa) signal sequence, a 263 aa propeptide, and a 139 aa growth factor domain (3, 4). The growth factor domain of human BMP-7 shares 98% aa sequence identity with mouse and rat BMP-7. The BMP-7 propeptide is cleaved intracellularly but remains in association with the growth factor domain. BMP-7 is subsequently secreted as a tetramer that consists of two propeptides and two disulfide-linked growth factor domains (5, 6). Mature BMP-7 can also form disulfide-linked heterodimers with BMP-2 or BMP-4, complexes that show increased potency and range of activity compared to BMP-7 homodimers (7-9). The presence of the propeptides in the BMP-7 tetramer does not diminish the bioactivity of the growth factor domains (6). Secreted BMP-7 is immobilized in the extracellular matrix as a result of interactions between the propeptide and matrix Fibrillin (5). BMP-7 exerts its biological effects through the type 2 receptors Activin RIIA, Activin RIIIB, and BMPRII and the type 1 receptors Activin RIA, BMPRII, and BMPRII (2, 6). BMP-7 plays a role in a variety of organ systems. It promotes new bone formation and nephron development (10, 11), inhibits the branching of prostate epithelium (12), and antagonizes epithelial-mesenchymal transition (EMT) (13-15). In pathological conditions, BMP-7 inhibits tumor growth and metastasis (14), ameliorates fibrotic damage in nephritis (13), and promotes neuroregeneration following brain ischemia (16).

References:

1. Carreira, A.C. *et al.* (2015) *J. Dent. Res.* **93**:335.
2. Weiskirchen, R. and S.K. Meurer (2013) *Front. Biosci. (Landmark Ed.)* **18**:1407.
3. Ozkaynak, E. *et al.* (1990) *EMBO J.* **9**:2085.
4. Celeste, A.J. *et al.* (1990) *Proc. Natl. Acad. Sci. USA* **87**:9843.
5. Gregory, K.E. *et al.* (2005) *J. Biol. Chem.* **280**:27970.
6. Sengle, G. *et al.* (2008) *J. Mol. Biol.* **381**:1025.
7. Israel, D.I. *et al.* (1996) *Growth Factors* **13**:291.
8. Aono, A. *et al.* (1995) *Biochem. Biophys. Res. Commun.* **210**:670.
9. Nishimatsu, S. and G.H. Thomsen (1998) *Mech. Dev.* **74**:75.
10. Sampath, T.K. *et al.* (1992) *J. Biol. Chem.* **267**:20352.
11. Kazama, I. *et al.* (2008) *J. Am. Soc. Nephrol.* **19**:2181.
12. Grishina, I.B. *et al.* (2005) *Dev. Biol.* **288**:334.
13. Zeisberg, M. *et al.* (2003) *Nat. Med.* **9**:964.
14. Buijs, J.T. *et al.* (2007) *Am. J. Pathol.* **171**:1047.
15. Yu, M.-A. *et al.* (2009) *J. Am. Soc. Nephrol.* **20**:567.
16. Chou, J. *et al.* (2006) *J. Neurol. Sci.* **240**:21.